Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MRNS

Marinus Pharmaceuticals (MRNS) Stock Price, News & Analysis

Marinus Pharmaceuticals logo

About Marinus Pharmaceuticals Stock (NASDAQ:MRNS)

Key Stats

Today's Range
$0.55
$0.55
50-Day Range
$0.55
$0.55
52-Week Range
$0.22
$1.97
Volume
260 shs
Average Volume
1.94 million shs
Market Capitalization
$30.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.92
Consensus Rating
Hold

Company Overview

Marinus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

MRNS MarketRank™: 

Marinus Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 643rd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Marinus Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.

  • Upside Potential

    Marinus Pharmaceuticals has a consensus price target of $3.92, representing about 613.3% upside from its current price of $0.55.

  • Amount of Analyst Coverage

    Marinus Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Marinus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Marinus Pharmaceuticals are expected to grow in the coming year, from ($1.99) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Marinus Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Marinus Pharmaceuticals has a P/B Ratio of 1.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for MRNS.
  • Dividend Yield

    Marinus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Marinus Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MRNS.
  • Search Interest

    1 people have searched for MRNS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Marinus Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.46% of the stock of Marinus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    98.80% of the stock of Marinus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Marinus Pharmaceuticals' insider trading history.
Receive MRNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MRNS Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
See More Headlines

MRNS Stock Analysis - Frequently Asked Questions

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its earnings results on Tuesday, August, 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.01. The biopharmaceutical company earned $8.06 million during the quarter, compared to analyst estimates of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 446.48% and a negative trailing twelve-month return on equity of 7,831.35%.
Read the conference call transcript
.

Marinus Pharmaceuticals's stock reverse split before market open on Wednesday, September 23rd 2020.The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Marinus Pharmaceuticals investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), DiamondRock Hospitality (DRH), American Water Works (AWK), AU Optronics (AUOTY) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/13/2024
Today
9/17/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MRNS
CIK
1267813
Employees
110
Year Founded
2003

Price Target and Rating

High Price Target
$10.00
Low Price Target
$0.50
Potential Upside/Downside
+613.3%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$141.40 million
Net Margins
-446.48%
Pretax Margin
-446.48%
Return on Equity
-7,831.35%
Return on Assets
-120.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.66
Quick Ratio
1.47

Sales & Book Value

Annual Sales
$30.99 million
Price / Sales
0.98
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
1.77

Miscellaneous

Outstanding Shares
55,220,000
Free Float
52,203,000
Market Cap
$30.32 million
Optionable
Optionable
Beta
1.03

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MRNS) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners